

Alaska Medicaid

XARELTO®(rivaroxaban)

Available 10mg, 15mg, and 20mg

INDICATIONS and USAGE:

“ XARELTO is a factor Xa inhibitor indicated:

- to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and PE
- for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery”¹

Criteria for Approval:

Atrial Fibrillation

- Diagnosis of non-valvular atrial fibrillation; **AND**
- Documented treatment failure of warfarin or clinically significant medical reason for non-trial of warfarin

Deep Vein Thrombosis or Pulmonary Embolism

- Treatment of deep vein thrombosis, pulmonary embolism and reduction in the risk of recurrence of DVT and of PE; **AND**
- Documented treatment failure of warfarin or clinically significant medical reason for non-trial of warfarin

Hip or Knee Replacement Surgery

- Prophylaxis of deep vein thrombosis (DVT) for knee or hip replacement surgery

Length of Authorization:

1. Non-valvular atrial fibrillation, prior authorization may be approved up to 12 months
2. Treatment of DVT, PE; prior authorization may be approved up to 12 months
3. Prophylaxis of Deep Vein Thrombosis:
 - a. Hip and knee replacement surgery, Date of Service

Dispensing Limit:

1. Prophylaxis of Deep Vein Thrombosis with a Quantity Limit of 1 dose per day:
 - Hip replacement surgery up to 34 days supply
 - Knee replacement surgery up to 12 days supply

References:

¹ Xarelto® package insert is available at:

http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100

Accessed 2/27/13

Xarelto criteria

Version 2

Last updated 3/12/2013

Approved 03/15/2013